Survival differences among women with de novo stage IV and relapsed breast cancer

Dawood, Shaheenah; Broglio, Kristine; Ensor, Joe; Hortobágyi, Gabriel N.; Giordano, Sharon H.

doi:10.1093/annonc/mdq220

Cited by 231 publications

(221 citation statements)

References 15 publications

Supporting

Mentioning

191

Contrasting

Unclassified

Order By: Relevance

“…El CM se presenta en la mayoría de los casos como una enfermedad localizada, sin embargo, hasta 30% de las pacientes pueden tener una recidiva de la enfermedad [10][11][12] . La presencia de enfermedad metastásica al debut, es un evento poco frecuente 10 .…”

Section: Discussionunclassified

See 1 more Smart Citation

Cáncer de mama metastásico: Caracterización de una cohorte según subtipos

Acevedo

et al. 2014

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

“…La presencia de enfermedad metastásica al debut, es un evento poco frecuente 10 . En nuestro Centro de Cáncer correspondió a menos de 4% del total de tumores invasores, un número similar a lo reportado en otras series 10,11 . El estudio del perfil de expresión génica en CM evidencia la existencia de una enfermedad heterogénea.…”

Section: Discussionunclassified

Cáncer de mama metastásico: Caracterización de una cohorte según subtipos

Acevedo

et al. 2014

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

“…11 As a result, some cases that might have been assigned as stage IIIc in countries that adhered to criteria in the sixth 10 Overall, the proportion of patients in this study with known HR status who had a primary diagnosis of HR-positive LA/MBC was lower (7.8%) than in previously published estimates (approximately 13%-17%). [6][7][8] However, the generalizability of the previous findings is limited, because they were derived from a small number of patient records. In addition, the range of years and geographic regions included in these studies differed from the present study, and comparisons should therefore be interpreted with caution.…”

Section: Esther Bastiaannet Et Almentioning

confidence: 99%

“…Studies of small retrospective databases have reported that of all patients with known HR status, approximately 13% to 17% had a primary diagnosis of HR-positive advanced disease (LA/MBC). [6][7][8] However, these studies did not assess subsequent therapy in this patient group, and, to our knowledge, a comprehensive evaluation of the size of this patient population has not been performed.…”

Section: Introductionmentioning

confidence: 99%

A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer

Bastiaannet

Charman

Johannesen

et al. 2018

Clinical Breast Cancer

View full text Add to dashboard Cite

In this observational study we estimated the proportion of postmenopausal breast cancer patients initially diagnosed with hormone receptor (HR)-positive locally advanced or metastatic breast cancer (LA/MBC), using data from 6 European cancer registries (n [ 244,268 with known HR status and disease stage). Approximately 19,002 patients (7.8%) received an initial diagnosis of HR-positive LA/MBC; 74.5% (n [ 14,157) of these received subsequent endocrine therapy as per guideline recommendations. Background: Despite guideline recommendations, reports suggest that a proportion of patients with hormone receptor (HR)-positive locally advanced or metastatic breast cancer (LA/MBC) might not receive endocrine therapy. The aims of this study were to estimate the proportion of postmenopausal patients with an initial (primary) diagnosis of HR-positive LA/MBC in Europe, and to assess the administration of endocrine treatment in these patients. Materials and Methods: Fourteen national and regional cancer registries across Europe were invited to participate in this observational study. Six registries each provided anonymized clinical information on > 5000 postmenopausal women with breast cancer diagnosed between January 2000 and December 2014, including age at diagnosis, estrogen and/or progesterone receptor status, disease stage, and receipt of endocrine therapy. The proportion of patients with an initial diagnosis of HR-positive LA/MBC and, of these, the proportion who received endocrine therapy, was calculated. Results: Registries from Belgium, England, Ireland, Norway, The Netherlands, and Munich, Germany provided data. In total, 316,680 postmenopausal women were diagnosed with breast cancer, including 244,268 with known HR status and disease stage. Of these patients, 19,002 (7.8%) had a primary diagnosis of HR-positive LA/MBC. This proportion ranged from 5.4% (N ¼ 4484) in England to 12.7% (N ¼ 4085) in Germany. Most of these patients (n ¼ 14,157; 74.5%) received endocrine treatment, ranging from 55.5% (n ¼ 445) in Clinical Breast Cancer Month 2017 -1 Norway to 88.1% (n ¼ 443) in Belgium. Conclusion: These results indicate that a sizeable proportion of postmenopausal patients in Europe received a primary diagnosis of HR-positive LA/MBC, and that almost threequarters received subsequent endocrine therapy as per guideline recommendations.

show abstract

“…Several studies 8,10,15,16 have also reported a range of prognostic factors for women with metastatic breast cancer, including factors such as age at diagnosis, hormone receptor status, human HER2 status, and site of metastases, for predicting survival from the time of metastases. In a cohort of 1,038 women with relapsed mBC, Largillier et al 16 reported that age at initial diagnosis, site of metastasis, and hormone receptor status were independent prognostic factors for survival following the development of metastatic disease.…”

mentioning

confidence: 99%

Treatment characteristics and mortality of a large insured female population with advanced or metastatic breast cancer by receipt of HER2-targeted agents

Hao

Meyer²,

Landsman-Blumberg³

et al. 2015

CER

View full text Add to dashboard Cite

Purpose: This retrospective administrative claims study of women diagnosed with advanced or metastatic breast cancer compared treatment characteristics and mortality by receipt of human epithelial growth factor receptor 2 (HER2)-targeted agents and by disease stage and age group among patients using HER2-targeted agents. Patients and methods: Adult women diagnosed with stage III or IV breast cancer (index date) between 2008 and 2012 were identified from MarketScan ® databases containing medical and pharmacy claims for .40 million enrollees insured with .100 US health plans. Patients were followed until the earlier of the following: end of enrollment, inpatient death, or December 31, 2012. Study cohorts were women ± HER2-targeted agent use, HER2-targeted agent users' subgroups of stages III and IV, and age group. Pre-and postindex breast cancer treatments were compared among study cohorts. Overall survival was compared using log-rank tests. Cox proportional-hazards models were used to study the predictors of overall survival. Results: Of 30,660 eligible women, 14.4% received HER2-targeted agents. HER2-targeted agent users received more aggressive pre-and postindex cancer treatments compared to those with no HER2-targeted agents. HER2-targeted agents had higher rates of pre-and postindex breast cancer surgery, adjuvant/neoadjuvant chemotherapy, radiation therapy, chemotherapy, and biologics-based therapy. Among HER2-targeted agent users, younger women and those with stage III breast cancer received more aggressive treatments. After adjusting for clinically relevant patient characteristics, women receiving HER2-targeted agents had a 20% reduced risk of death compared to patients not receiving HER2-targeted agents. Among all patients and the subset of HER2-targeted agent users, stage IV patients and those in the oldest age group had a higher risk of death. Conclusion: Among patients with advanced or metastatic breast cancer, receipt of HER2-targeted agents was associated with more aggressive treatment and longer survival. Patients with higher stage breast cancer and older patients received less aggressive therapies and had a higher risk of death.

show abstract

Survival differences among women with de novo stage IV and relapsed breast cancer

Abstract: This large cohort study provides further insight into the natural history of relapsed and de novo stage IV breast cancer. DFI plays an important role in the prognosis for patients with relapsed breast cancer.

Cited by 231 publications

References 15 publications

Cáncer de mama metastásico: Caracterización de una cohorte según subtipos

Cáncer de mama metastásico: Caracterización de una cohorte según subtipos

A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer

Treatment characteristics and mortality of a large insured female population with advanced or metastatic breast cancer by receipt of HER2-targeted agents

Contact Info

Product

Resources

About